中銀保監計劃上半年發布償二代二期工程20項監管規則
面對嚴峻複雜的國內外形勢特別是新冠肺炎疫情的嚴重衝擊,中國銀保監會堅決深化保險業償付能力監管改革,積極防範化解重點公司和重點領域風險。中銀保監表示,內地保險業2020年全年運行穩健,償付能力指標保持在合理區間,風險總體可控。
對於2021年重點工作安排,中銀保監計劃今年上半年發布償二代二期工程20項監管規則,積極推動出台保險公司發行無固定期限資本補充債券等新型資本補充工具相關政策,強化償付能力監管剛性約束。
具體政策還包括:提升償付能力風險監測的數字化和智能化水平,增強監測的敏感性、及時性和可靠性;持續推進償付能力監管國際合作,更新與香港的等效評估工作框架協議,延長對香港的過渡期便利政策等。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.